Evidence map›Paper›PMID 37830597›Full record

ArticleCells2023

Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus.

Gustavo Garcia, Nikhil Chakravarty, Sophia Paiola, Estrella Urena, Priya Gyani, Christopher Tse, Samuel W French, Moise Danielpour, Joshua J Breunig, David A Nathanson and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Gustavo GarciaDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-1649-9251
Nikhil ChakravartyDepartment of Epidemiology, University of California Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-4603-1713
Sophia PaiolaDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Estrella UrenaDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Priya GyaniDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Christopher TseDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Samuel W FrenchDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
Moise DanielpourDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.ORCID 0000-0002-8187-9234
Joshua J BreunigDepartment of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
Vaithilingaraja ArumugaswamiDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA 90095, USA.
University of California, Los Angeles · USCedars-Sinai Medical Center · USCalifornia NanoSystems Institute · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Metabolic and epigenetic reprogramming of vital organs in SARS-CoV-2 induced systemic toxicityR01DK132735 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARUMUGASWAMI, VAITHILINGARAJA, DEB, ARJUN · 2021 to 2023
$6.0M
Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Developing three-dimensional antisense oligonucleotide drugs against COVID-19R01AI163216 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GUO, FENG · 2021 to 2025
$2.3M
GESTALT Barcoding and Single-cell Transcriptomics of Tumor Cell Evolution in Personalized Tumor ModelsR33CA236687 · NCI · CEDARS-SINAI MEDICAL CENTER · PI BREUNIG, JOSHUA JOHN · 2019 to 2021
$1.2M
NCI NIH HHS P50 CA211015NCI NIH HHS R33 CA236687NEI NIH HHS R01 EY032149NIAID NIH HHS R01 AI163216NIDDK NIH HHS R01 DK132735
6 · The paper itself

Abstract

Glioblastoma (GBM), the most common primary malignant brain tumor, is a highly lethal form of cancer with a very limited set of treatment options. High heterogeneity in the tumor cell population and the invasive nature of these cells decrease the likely efficacy of traditional cancer treatments, thus requiring research into novel treatment options. The use of oncolytic viruses as potential therapeutics has been researched for some time. Zika virus (ZIKV) has demonstrated oncotropism and oncolytic effects on GBM stem cells (GSCs). To address the need for safe and effective GBM treatments, we designed an attenuated ZIKV strain (ZOL-1) that does not cause paralytic or neurological diseases in mouse models compared with unmodified ZIKV. Importantly, we found that patient-derived GBM tumors exhibited susceptibility (responders) and non-susceptibility (non-responders) to ZOL-1-mediated tumor cell killing, as evidenced by differential apoptotic cell death and cell viability upon ZOL-1 treatment. The oncolytic effect observed in responder cells was seen both in vitro in neurosphere models and in vivo upon xenograft. Finally, we observed that the use of ZOL-1 as combination therapy with multiple PI3K-AKT inhibitors in non-responder GBM resulted in enhanced chemotherapeutic efficacy. Altogether, this study establishes ZOL-1 as a safe and effective treatment against GBM and provides a foundation to conduct further studies evaluating its potential as an effective adjuvant with other chemotherapies and kinase inhibitors.

Indexed as

GlioblastomaOncolytic VirotherapyZika VirusZika Virus InfectionAnimalsHumansMicePhosphatidylinositol 3-KinasesPhosphatidylinositol 3-Kinasesapoptosisglioblastomaneurosphereoncolytic virusZika virus

Identifiers

PMID37830597
PMCPMC10572118
OpenAlexW4387185613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.